Oxford Ledge
Search
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a biotechnology company trading at $2.54 (−10.9% today). Figures from SEC EDGAR and market feeds; updated 2026-07-15 04:49 UTC.
This company is a clinical-stage biopharmaceutical firm developing AD04, an investigational drug for treating alcohol use disorder in patients with specific genetic markers identified through a companion diagnostic test. The company tested AD04 in the ONWARD Phase 3 clinical trial and is now focused on completing clinical development in identified genetic subgroups to meet regulatory requirements in the US and Europe. The company has not generated significant revenue since inception and has not received marketing approval for any products.
Summarized from Adial Pharmaceuticals, Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $2.54 |
| Change (1D) | -0.31 (-10.88%) |
| Volume | 241.1K shares |
| 52-week range | $1.31 – $19.00 |
| Returns | |
| 52-week return | +93.9% |
This company is a clinical-stage biopharmaceutical firm developing AD04, an investigational drug for treating alcohol use disorder in patients with specific genetic markers identified through a companion diagnostic test.
ADIL trades at $2.54, as of 2026-07-15.
Adial Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-07-15 04:49 UTC. This page is also available as JSON at /api/data?ticker=ADIL and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ADIL and 3,500+ tickers.
Create a free account — keep ADILGET /api/data?ticker=ADIL
This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt